Group 1: TeBao Bio - TeBao Bio is focusing on functional cure for hepatitis B, aiming for a combination of different mechanism drugs with interferons and nucleos(t)ide analogs for optimization [1] - The company is collaborating with Ligos to explore reinfection control after clearing infected cells and has acquired JiuTian Bio to leverage its gene therapy platform for more precise solutions [1] - New technologies like siRNA have entered the clinical combination application stage, with future strategies focusing on optimizing combination therapies [1] Group 2: Cambridge Technology - Cambridge Technology's main business with North American operators is concentrated in broadband access and wireless networks, with unclear business planning for 2027 [1] - The company is making progress with several major North American clients, with some product verifications nearing completion while others are still ongoing [1] - The production capacity for the 800G series products at Shanghai and JiaShan factories is being increased to an annualized 2 million units, with plans for further expansion in the first half of next year [1] Group 3: Hive Fund - Hive Fund was established in 2018, with a total asset management scale of 48.884 billion yuan, ranking 86th out of 210 [2] - The fund's scale for non-monetary public funds is 48.879 billion yuan, ranking 76th out of 210 [2] - The best-performing public fund product in the past year is the Hive Advanced Manufacturing Mixed Initiation A, with a latest net value of 1.27 and a growth of 63.35% over the past year [2]